Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight

The demand for minimal residual disease testing is increasing mainly due to the higher prevalence of solid tumors and blood cancers like leukemia, multiple myeloma, and lymphoma. Continuous advances in molecular diagnostics have greatly improved MRD detection accuracy, and active product...